| Literature DB >> 25136645 |
Chuang Yuan1, Christopher W K Lai1, Lawrence W C Chan1, Meyrick Chow2, Helen K W Law1, Michael Ying1.
Abstract
AIMS: To comprehensively evaluate the effect of a short-term diabetes self-management education (DSME) on metabolic markers and atherosclerotic parameters in patients with type 2 diabetes.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25136645 PMCID: PMC4127232 DOI: 10.1155/2014/789761
Source DB: PubMed Journal: J Diabetes Res Impact factor: 4.011
The content of the diabetes self-management education for the patients in the intervention group.
| Contents | |
|---|---|
| Healthy eating | (i) Common misunderstanding of diet for self-management of type 2 diabetes mellitus |
| (ii) The types of healthy and unhealthy foods for type 2 diabetics | |
| (iii) The benefits of health foods and the drawbacks of unhealthy foods for type 2 diabetics | |
| (iv) Recognition of healthy foods based on food package | |
| (v) Healthy cooking methods for type 2 diabetics | |
| (vi) Appropriate caloric intake for type 2 diabetics | |
| (vii) A brief method for counting calories of foods | |
| (viii) The best time to eat | |
|
| |
| Being active | (i) The importance of regular exercise for type 2 diabetics |
| (ii) Common misunderstanding of exercise for self-management of type 2 diabetes mellitus | |
| (iii) Suitable types of exercise for type 2 diabetics | |
| (iv) Individualized plan for regular exercise | |
| (v) Self-check and control of body weight | |
|
| |
| Monitoring | (i) The importance of regular monitoring of blood glucose |
| (ii) Methods of self-monitoring of blood glucose | |
| (iii) Self-management of blood glucose | |
|
| |
| Taking medication | (i) Pathology and medical treatments of type 2 diabetes mellitus |
| (ii) The importance of taking diabetic medications | |
| (iii) Efficacies and side effects of different diabetic medications | |
| (iv) The appropriate time and frequency of taking diabetic medications | |
|
| |
| Problem solving | (i) Choosing healthy foods under various circumstances |
| (ii) Doing appropriate exercises according to individual health status | |
| (iii) Methods to handle abnormal blood glucose | |
|
| |
| Reducing risks | (i) Common complications of type 2 diabetes mellitus |
| (ii) Risk factors of diabetic complications | |
| (iii) The importance of stopping unhealthy behaviors (e.g., smoking) and maintaining healthy lifestyles | |
|
| |
| Healthy coping | (i) The importance of self-management of type 2 diabetes mellitus |
| (ii) Designing an individualized plan for self-management of type 2 diabetes mellitus | |
Figure 1The assessment of intima-media thickness and arterial stiffness in the carotid artery. (a) Radiofrequency-based quality intima-media thickness. (b) Radiofrequency-based quality arterial stiffness. The arrows indicate the inferior end of the carotid bulb and the double-arrow lines show a distance of 1 cm.
Comparison of ultrasound parameters of the carotid artery and metabolic markers between the baseline and follow-up assessments in the intervention and control groups.
| Intervention ( | Control ( | |||||
|---|---|---|---|---|---|---|
| #Baseline | Follow up |
| #Baseline | Follow up |
| |
| Age, years | 58.9 ± 8.4 | — | — | 57.8 ± 8.2 | — | — |
| Gender, female/male, | 22/14 | — | — | 28/12 | — | — |
| Duration of diabetes, years | 8.7 ± 6.9 | — | — | 7.3 ± 6.4 | — | — |
| IMT, | 702.3 ± 127.7 | 678.9 ± 126.2 | 0.025∗ | 693.4 ± 127.3 | 687.1 ± 135.5 | 0.579 |
| DC, 1/KPa | 0.017 ± 0.009 | 0.016 ± 0.005 | 0.821 | 0.016 ± 0.006 | 0.017 ± 0.006 | 0.529 |
| CC, mm2/KPa | 0.731 ± 0.284 | 0.730 ± 0.266 | 0.660 | 0.753 ± 0.262 | 0.735 ± 0.279 | 0.525 |
|
| 6.081 ± 2.190 | 5.551 ± 1.784 | 0.122 | 5.551 ± 1.558 | 5.5597 ± 1.800 | 0.124 |
|
| 12.373 ± 4.418 | 11.280 ± 3.612 | 0.099 | 11.289 ± 3.148 | 11.400 ± 3.640 | 0.677 |
| PWV, m/s | 8.428 ± 1.618 | 8.078 ± 1.487 | 0.177 | 7.911 ± 1.177 | 8.028 ± 1.436 | 0.584 |
| Blood glucose, mmol/L | 7.689 ± 1.639 | 7.517 ± 1.602 | 0.238 | 7.968 ± 1.729 | 8.128 ± 1.771 | 0.427 |
| Total cholesterol, mmol/L | 4.664 ± 0.944 | 4.440 ± 0.961 | 0.034∗ | 4.865 ± 0.879 | 4.550 ± 0.714 | <0.001∗ |
| HDL, mmol/L | 1.320 ± 0.297 | 1.343 ± 0.325 | 0.160 | 1.320 ± 0.337 | 1.281 ± 0.340 | 0.303 |
| LDL, mmol/L | 2.810 ± 0.768 | 2.590 ± 0.844 | 0.005∗ | 2.927 ± 0.748 | 2.631 ± 0.674 | <0.001∗ |
| Triglyceride, mmol/L | 1.162 ± 0.644 | 1.112 ± 0.591 | 0.626 | 1.345 ± 0.841 | 1.389 ± 0.753 | 0.850 |
| HbA1c, % | 6.970 ± 0.915 | 6.772 ± 0.767 | 0.039∗ | 7.038 ± 1.042 | 7.118 ± 1.300 | 0.102 |
| Weight, kg | 60.25 ± 9.54 | 59.06 ± 9.03 | <0.001∗ | 65.66 ± 13.38 | 65.05 ± 12.71 | 0.066 |
| BMI, kg/m2 | 23.82 ± 4.57 | 23.25 ± 4.14 | <0.001∗ | 25.42 ± 4.65 | 25.03 ± 4.35 | 0.019∗ |
| SBP, mmHg | 127.1 ± 17.7 | 125.9 ± 16.1 | 0.692 | 122.5 ± 14.8 | 124.8 ± 17.6 | 0.498 |
| DBP, mmHg | 75.3 ± 9.0 | 75.2 ± 7.3 | 0.916 | 73.0 ± 10.1 | 75.1 ± 10.2 | 0.221 |
#No significant difference (P > 0.05) was found in age, gender, duration of type 2 diabetes, metabolic markers, CIMT, and CAS between the intervention and control groups in the baseline assessment.
*P value indicates significant difference between baseline and follow-up examination in either intervention group or control group. IMT: intima-media thickness; DC: distensibility coefficient; CC: compliance coefficient; PWV: pulse wave velocity; HDL: high density lipoprotein; LDL: low density lipoprotein; HbA1c: hemoglobin A1c; BMI: body mass index; SBP: systolic blood pressure; and DBP: diastolic blood pressure.
Change of characteristics of subjects from baseline to follow-up assessments in the intervention and control groups.
| Characteristics | Intervention | Control |
|
|---|---|---|---|
| ΔIMT, | −23.3 ± 68.1 | −6.3 ± 71.4 | 0.298 |
| ΔDC, 1/KPa | −0.002 ± 0.01 | 0.001 ± 0.008 | 0.317 |
| ΔCC, mm2/KPa | 0.018 ± 0.200 | −0.012 ± 0.236 | 0.487 |
| Δ | −0.531 ± 2.018 | 0.046 ± 1.637 | 0.185 |
| Δ | −1.093 ± 4.009 | 0.118 ± 3.334 | 0.193 |
| ΔPWV, m/s | −0.351 ± 1.530 | 0.117 ± 1.339 | 0.159 |
| ΔBlood glucose, mmol/L | −0.172 ± 1.400 | 0.160 ± 0.956 | 0.149 |
| ΔTotal cholesterol, mmol/L | −0.219 ± 0.546 | −0.315 ± 0.527 | 0.351 |
| ΔHDL, mmol/L | 0.024 ± 0.161 | −0.039 ± 0.173 | 0.596 |
| ΔLDL, mmol/L | −0.220 ± 0.446 | −0.296 ± 0.489 | 0.106 |
| ΔTriglyceride, mmol/L | −0.050 ± 0.425 | 0.044 ± 0.583 | 0.643 |
| ΔHbA1c, % | −0.200 ± 0.560 | 0.080 ± 0.741 | 0.004∗ |
| ΔWeight, kg | −1.19 ± 1.39 | −0.61 ± 2.04 | 0.036∗ |
| ΔBMI, kg/m2 | −0.57 ± 1.00 | −0.39 ± 1.00 | 0.105 |
| ΔSBP, mmHg | −1.36 ± 16.70 | 2.34 ± 15.24 | 0.388 |
| ΔDBP, mmHg | −0.05 ± 9.54 | 2.25 ± 9.74 | 0.223 |
*P value indicates significant difference in changes of variables between the intervention group and control groups. IMT: intima-media thickness; DC: distensibility coefficient; CC: compliance coefficient; PWV: pulse wave velocity; HDL: high density lipoprotein; LDL: low density lipoprotein; HbA1c: hemoglobin A1c; BMI: body mass index; SBP: systolic blood pressure; and DBP: diastolic blood pressure.